CohBar to Present at the BIO Investor Forum
October 05, 2020 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference
September 29, 2020 16:05 ET
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit
September 10, 2020 16:05 ET
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the H.C. Wainwright Annual Global Investment Conference
September 03, 2020 08:45 ET
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Announces Closing of Public Offering of Common Stock and Warrants
August 28, 2020 16:05 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
August 26, 2020 08:30 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
CohBar Announces Proposed Public Offering of Common Stock and Warrants
August 25, 2020 16:55 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
August 24, 2020 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update
August 13, 2020 16:03 ET
|
CohBar, Inc.
New positive preliminary preclinical results in ARDS modelCompany to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:...
CohBar Presents New Antifibrotic Data at the American Thoracic Society’s Virtual 2020 Conference
August 05, 2020 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...